Tillotts to acquire global rights for Entocort from AstraZeneca outside the US
9 July 2015 | By Victoria White
Tillotts Pharma has entered into an agreement for the acquisition of the global rights for Entocort from AstraZeneca, excluding the US...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
9 July 2015 | By Victoria White
Tillotts Pharma has entered into an agreement for the acquisition of the global rights for Entocort from AstraZeneca, excluding the US...
15 June 2015 | By Victoria White
AstraZeneca presented results from its Phase III trial investigating lesinurad in combination with febuxostat in patients with tophaceous gout at EULAR 2015...
2 June 2015 | By Victoria White
Draft guidance issued by NICE on the drug olaparib do not recommend its use for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
1 June 2015 | By Victoria White
AstraZeneca has announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of EGFRm advanced non-small cell lung cancer (NSCLC)...
26 May 2015 | By Victoria White
Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab...
24 April 2015 | By Victoria White
Innate Pharma has signed a co-development and commercialisation agreement with AstraZeneca to accelerate and broaden the development of IPH2201...
17 April 2015 | By Victoria White
Latest data from the ongoing AURA study of AZD9291 demonstrated a median progression free survival of 13.5 months in patients with advanced EGFRm NSCLC...
20 March 2015 | By Victoria White
Daiichi Sankyo has announced a co-commercialisation agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US with plans to launch in April 2015..
9 February 2015 | By Pharmaceutical Licensing Group
Pharmaceutical Licensing Group has announced the results of its 8th Annual Awards for excellence in business development which were given at its AGM on 5th February 2015...
4 February 2015 | By AstraZeneca
AstraZeneca announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City...
30 January 2015 | By AstraZeneca and The University of Texas MD Anderson Cancer Center
AstraZeneca and The University of Texas MD Anderson Cancer Center announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes...
29 January 2015 | By AstraZeneca
AstraZeneca has announced 4 research collaborations aimed at harnessing CRISPR, a pioneering genome-editing technique, across its entire discovery platform...
7 November 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue...
3 November 2014 | By Almirall
Almirall announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall’s respiratory franchise after all closing conditions have been satisfied...
20 October 2014 | By AstraZeneca
AstraZeneca, together with its global biologics research and development arm, MedImmune, announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership...